Edit |   |
Antigenic Specificity | Human CD33 |
Clone | [FOS] |
Host Species | Mouse |
Reactive Species | human |
Isotype | IgG1 |
Format | Protein A purified |
Size | 0.1 mg |
Concentration | n/a |
Applications | Flow Cytometry (FC/FACS) |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | Identification of human Monocytes (bright) and Granulocytes (dim) expressing the 67kDa M.W. surface antigen. CD33 is also found on CFU-mix, CFU-GM, CFU-Meg, a portion of BFU-E, myeloblasts, promyelocytes, myelocytes, metamyelocytes but not early precursors |
Immunogen | Immunogen: CD33=Derived from the hybridization of mouse Sp2/0 myeloma cells with spleen cells from BALB/c mice immunized with FMY9S5 cells containing the CD33 gene. |
Other Names | [CD33], [CD33; CD33; p67; SIGLEC3; SIGLEC-3; SIGLEC3; Siglec-3] |
Gene, Accession # | [CD33], Gene ID: 945, NCBI: P20138.2, UniProt: P20138 |
Catalog # | MBS397654 |
Price | $230 |
Order / More Info | Human CD33 Antibody from MYBIOSOURCE INC. |
Product Specific References | 1. Comparsion of outcome, clinical, laboratory, and immunological features in 164 children and adults with T-ALL. Garand, R., Vannier, J.P., Bene, M.C., Faure, G., Favre, M., Bernard, A,. Leukemia,1990 No;4(11):739-44. 2. Immunologic Classification of Leukemia and Lymphoma. Foon, K.A., Todd, III,R.F. (1986)(1986) Blood,68, 1 3. Surface marker expression in acute myeloid leukaemia at first relapse. Thomas X; Campos L; Archimbaud E; Shi ZH; TreilleRitouet D; Anglaret B; Fiere D Br J Haematol 1992 May;81(1):40-4 4. Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia. Robertson MJ; Soiffer RJ; Freedman AS; Rabinowe SL; Anderson KC; Ervin TJ; Murray C; Dear K; Griffin JD; Nadler LM; et al Blood 1992 May 1;79(9):2229-36 5. Expression of myeloid differentiation antigens in acute nonlymphocytic leukemia: increased concentration of CD33 antigen predicts poor outcome--a report from the Childrens Cancer Study Group. Dinndorf PA; Buckley JD; Nesbit ME; Lampkin BC; Piomelli S; Feig SA; Kersey JH; Hammond GD; Bernstein ID Med Pediatr Oncol 1992;20(3):192-200 6. Differences in the frequency of normal and clonal precursors of colony-forming cells in chronic myelogenous leukemia and acute myelogenous leukemia. Bernstein ID; Singer JW; Smith FO; Andrews RG; Flowers DA; Petersens J; Steinmann L; Najfeld V; Savage D; Fruchtman S; et al Blood 1992 Apr 1;79(7):1811-6 7. The role of an anti-myeloperoxidase antibody in the diagnosis and classification of acute leukaemia: a comparison with light and electron microscopy cytochemistry. Buccheri V; Shetty V; Yoshida N; Morilla R; Matutes E; Catovsky D Br J Haematol 1992 Jan;80(1):62-8 |